Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-articular Xcel-m-condro-alfa for knee osteoarthritis
2009-016449-24Phase 2Completed
- Sponsor
- Banc de Sang i Teixits
- Start
- Jan 2010
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of XCEL-M-ALPHA in knee osteoarthritis (OA), sponsored by Banc de Sang i Teixits. Primary endpoints: Efficacy at 6 and 12 months, Feasibility and safety and 1 more. Started Jan 2010; status: completed.
02
Drugs
XCEL-M-ALPHA
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2009-016449-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016449-24.